PROGRAMS ON DEMAND
CUA Members: Log in to access printable versions and to download the tools directly to your preferred device.
QUICK LINKS:
F. Saad, R. Hamilton, D. Laidley
PSMA: From Molecular Imaging to Radioligand Therapy
K. Fizazi
Treatment Intensification across the Spectrum of Hormone Sensitive Disease
W. Kassouf & A. Lalani
Multidisciplinary Management of Bladder Cancer
A. Macedo, C. Koo, J. de Jesus
Collaborative Practice in Prostate Cancer: How is this actually done?
CUAJ October 2022: Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada
F. Saad & U. Emmenegger
Treatment Evolutions & Approaches in the Management of Prostate Cancer: Bridging the Gap between Science and Patients
R. Rendon, S. Hotte, S. Morgan, P. Black, M. Jiang, M. Huynh, L. Wood
CUA Highlights of ESMO 2022
F. Saad, R. Rendon, A. Aprikian, A. Feifer, A. Kokorovic
CUA Guideline on ADT: Adverse Events and Management Strategies [UPDATE 2022]
CANADIAN URINARY DIVERSIONS POSITION STATEMENT
R. Rendon, A. Morgans, R. Lopes
How have the recent clinical trials in Prostate Cancer informed my practice choices?
The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.
For comments or information, email Corporate.office@cua.org